Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885335 | 0.92 | GPR84 (0.39) | FDPS | |
| SCHEMBL6988843 | 0.90 | SHBG (0.39) | METAP1TSHR | |
| SCHEMBL7458138 | 0.84 | SHBG (0.38) | TSHR | |
| SCHEMBL7457424 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL7457530 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL7458659 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL7463334 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL7453115 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL7452808 | 0.83 | TSHR (0.38) | TSHR | |
| SCHEMBL6589844 | 0.78 | DNM1 (0.31) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| EP-2010541-A2 | TRANS-FUSED CHROMENOISOQUINOLINES, SYNTHESIS AND METHODS FOR USE | Purdue Research Foundation (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007098462-A2 | TRANS-FUSED CHROMENOISOQUINOLINES, SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | SLC6A3, HTR3B, SLC18A2 | METAP1 3441/4885TSHR 38/4885SMN1; SMN2 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.